药物研发公司 Recursion 于 11 月 6 日发布第三季度业绩，跳过财报电话会议，11 月 20 日更新合并情况。 Recursion, a drug discovery firm, releases Q3 results Nov 6, skips earnings call, updates on merger Nov 20.
专注于药物发现的临床阶段生物技术公司Recursion将于2024年11月6日发布其第三季度的业绩,但不会举行传统的财报会议. Recursion, a clinical-stage techbio firm focused on drug discovery, will release its Q3 2024 results on November 6, 2024, but will not hold a traditional earnings call. 相反,在其拟议的与Exscientia合并之后,将在2024年11月20日进行更新. Instead, an update will follow its proposed merger with Exscientia on November 20, 2024. 电话会议将在社交媒体平台上直播，允许观众提问。 The call will be streamed on social media platforms, allowing for viewer questions. Recursion总部设在盐湖城,使用先进的机器学习,以加强毒品发现。 Headquartered in Salt Lake City, Recursion employs advanced machine learning to enhance drug discovery.